5 Key Takeaways

• 1

  VERVE-102 is a one-time base editing therapy that inactivates PCSK9, showing significant cholesterol reduction in a phase 1 study.

• 2

  The therapy produced up to 88% reduction in PCSK9 and 62% reduction in LDL-C, with effects lasting over a year in some participants.

• 3

  Eli Lilly acquired Engage Bio to enhance its genetic medicines portfolio with non-viral DNA delivery technologies.

• 4

  Korecyte Bio is developing a tumour-activated CAR-T therapy platform aimed at improving treatment for solid cancers.

• 5

  Scribe Therapeutics has received clearance for a first-in-human study of STX-1150, a CRISPR-based therapy targeting PCSK9.